The FDA has given the green light to Sanofi’s drug Dupixent to be used as treatment in pediatric patients with chronic eosinophilic esophagitis, the pharmaceutical company announced Jan. 25.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
